Evidence map›Paper›PMID 40642733›Full record

ArticleCureus2025

Managing Stroke Risk in Moyamoya Disease With Paroxysmal Atrial Fibrillation: A Case Report.

Ahmed Kazi, Aniq Saleem, Abeera Akram

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ahmed KaziInternal Medicine, Saint Francis Hospital, Hartford, USA.
Aniq SaleemMedicine, Fatima Memorial Hospital, Lahore, PAK.
Abeera AkramCardiology, University of Connecticut, Farmington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Moyamoya disease is a progressive cerebrovascular disorder characterized by the narrowing and occlusion of arteries at the base of the brain, leading to the development of collateral vessels, which increases the risk of both ischemic and hemorrhagic strokes. The presence of atrial fibrillation (AF), particularly in a patient with Moyamoya disease, complicates the management strategy due to the dual risks of thromboembolism and hemorrhage. We present a case of a 40-year-old female with a history of unilateral right-brain Moyamoya disease, treated surgically, and with two prior strokes, left carotid stenosis, and hypertension. She was undergoing evaluation for arrhythmia with an implantable loop recorder (ILR) in place and presented to the ED with palpitations. Her ILR was interrogated, revealing two episodes of paroxysmal AF. Heart rate control was achieved with beta-blockers. Due to an elevated CHA₂DS₂-VASc score of 5, anticoagulation was recommended. However, there was concern about the increased risk of spontaneous cerebral hemorrhage in the setting of Moyamoya disease. After consulting with a neurologist and weighing the risks versus benefits, the patient was started on apixaban. Regarding the management of her AF, the patient expressed interest in pursuing catheter ablation; however, the procedure had not been performed at the time of this report. This case highlights the complexity of managing patients with both Moyamoya disease and paroxysmal AF. Treatment should be individualized, considering the benefits and risks of anticoagulation versus antiplatelet therapy, with an emphasis on stroke prevention while minimizing the risk of bleeding.

Indexed as

anticoagulationantiplatelet therapyatrial fibrillationcatheter ablationcerebrovascular diseasecollateral vesselscoronary artery diseasehypertensionmoyamoya diseasestroke

Identifiers

PMID40642733
PMCPMC12245140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.